Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 1114-1121

  Hadaczek, Piotr ^a   Johnston, Louisa ^a   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Convection enhanced delivery (CED); Glial cell line derived factor (GDNF); Neurturin (NTN); Rat

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MALE; NEURTURIN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 77950951527     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.02.002     Document Type: Article

References (41)

1. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3:383-394.
2. Airaksinen M.S., Titievsky A., Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant?. Mol. Cell. Neurosci. 1999, 13:313-325.
3. Akerud P., Canals J.M., Snyder E.Y., Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J. Neurosci. 2001, 21:8108-8118.
4. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad Sci. USA 1994, 91:2076-2080.
5. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
6. Curtis M.A., Kam M., Nannmark U., Anderson M.F., Axell M.Z., Wikkelso C., Holtas S., van Roon-Mom W.M., Bjork-Eriksson T., Nordborg C., Frisen J., Dragunow M., Faull R.L., Eriksson P.S. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 2007, 315:1243-1249.
7. Eriksson P.S., Perfilieva E., Bjork-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in the adult human hippocampus. Nat. Med. 1998, 4:1313-1317.
8. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann. Neurol. 2005, 58:224-233.
9. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
10. Gianino S., Grider J.R., Cresswell J., Enomoto H., Heuckeroth R.O. GDNF availability determines enteric neuron number by controlling precursor proliferation. Development 2003, 130:2187-2198.
11. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
12. Grondin R., Zhang Z., Ai Y., Ding F., Walton A.A., Surgener S.P., Gerhardt G.A., Gash D.M. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant. 2008, 17:373-381.
13. Hadaczek P., Yamashita Y., Mirek H., Tamas L., Bohn M.C., Noble C., Park J.W., Bankiewicz K. The ″ perivascular pump″ driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 2006, 14:69-78.
14. Hebert M.A., Van Horne C.G., Hoffer B.J., Gerhardt G.A. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J. Pharmacol. Exp. Ther. 1996, 279:1181-1190.
15. Henderson C.E., Phillips H.S., Pollock R.A., Davies A.M., Lemeulle C., Armanini M., Simmons L., Moffet B., Vandlen R.A., Simpson L.C., et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994, 266:1062-1064.
16. Heuckeroth R.O., Lampe P.A., Johnson E.M., Milbrandt J. Neurturin and GDNF promote proliferation and survival of enteric neuron and glial progenitors in vitro. Dev. Biol. 1998, 200:116-129.
17. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson E., Milbrandt J., Rosenthal A., Bjorklund A., Vandlen R.A., Hynes M.A., Phillips H.S. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 1998, 18:4929-4937.
18. Hovland D.N., Boyd R.B., Butt M.T., Engelhardt J.A., Moxness M.S., Ma M.H., Emery M.G., Ernst N.B., Reed R.P., Zeller J.R., Gash D.M., Masterman D.M., Potter B.M., Cosenza M.E., Lightfoot R.M. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007, 35:1013-1029.
19. Johnston L.C., Eberling J., Pivirotto P., Hadaczek P., Federoff H.J., Forsayeth J., Bankiewicz K.S. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene. Ther. 2009, 20:497-510.
20. Kirik D., Georgievska B., Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 2004, 7:105-110.
21. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J., Gasmi M., Bartus R.T. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 2006, 60:706-715.
22. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson E.M., Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996, 384:467-470.
23. Krauze M.T., Saito R., Noble C., Tamas M., Bringas J., Park J.W., Berger M.S., Bankiewicz K. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 2005, 103:923-929.
24. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
25. Lapchak P.A., Gash D.M., Collins F., Hilt D., Miller P.J., Araujo D.M. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp. Neurol. 1997, 145:309-321.
26. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
28. Manfredsson F.P., Tumer N., Erdos B., Landa T., Broxson C.S., Sullivan L.F., Rising A.C., Foust K.D., Zhang Y., Muzyczka N., Gorbatyuk O.S., Scarpace P.J., Mandel R.J. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol. Ther. 2009, 17:980-991.
29. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P.A., Collins F., Hilt D., Lebel C., Kryscio R., Gash D.M. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 1997, 42:208-214.
30. Natarajan D., Marcos-Gutierrez C., Pachnis V., de Graaff E. Requirement of signalling by receptor tyrosine kinase RET for the directed migration of enteric nervous system progenitor cells during mammalian embryogenesis. Development 2002, 129:5151-5160.
31. Oiwa Y., Yoshimura R., Nakai K., Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res. 2002, 947:271-283.
32. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11:755-761.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Elsevier Academic Press.
34. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 1999, 11:1554-1566.
35. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998, 82:129-137.
36. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
37. Stewart A.L., Anderson R.B., Kobayashi K., Young H.M. Effects of NGF, NT-3 and GDNF family members on neurite outgrowth and migration from pelvic ganglia from embryonic and newborn mice. BMC Dev. Biol. 2008, 8:73.
38. Su X., Kells A.P., Huang E.J., Lee H.S., Hadaczek P., Beyer J., Bringas J., Pivirotto P., Penticuff J., Eberling J., Federoff H.J., Forsayeth J., Bankiewicz K.S. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum. Gene Ther. 2009, 20:1627-1640.
39. Taraviras S., Marcos-Gutierrez C.V., Durbec P., Jani H., Grigoriou M., Sukumaran M., Wang L.C., Hynes M., Raisman G., Pachnis V. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development 1999, 126:2785-2797.
40. Tatarewicz S.M., Wei X., Gupta S., Masterman D., Swanson S.J., Moxness M.S. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 2007, 27:620-627.
41. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.